InjectionClinical Overview
Amikacin is a semisynthetic aminoglycoside bactericidal antibiotic derived from kanamycin. It irreversibly binds to the bacterial 30S ribosomal subunit, inducing misreading of mRNA genetic code and interfering with protein translation. Particularly effective against multidrug-resistant Gram-negative bacillary infections (Pseudomonas aeruginosa, Klebsiella, Enterobacter, Proteus, Serratia, and E. coli) and Mycobacterium tuberculosis in specialized second-line regimens.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administered strictly by a qualified healthcare professional via intramuscular (IM) injection or slow intravenous (IV) infusion over 30 to 60 minutes. Not absorbable by the oral route. Dosage is calculated accurately based on ideal body weight and renal function.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Local injection pain, headache, mild nausea. Rare/Severe: Nephrotoxicity (elevation of serum creatinine, azotemia, acute tubular necrosis), ototoxicity (cochlear hearing loss and irreversible vestibular dysfunction), and neuromuscular blockade/respiratory paralysis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: Nephrotoxicity and ototoxicity. Pre-existing renal impairment, dehydration, advanced age, and high trough levels heighten toxicity risk. Monitor serum creatinine, BUN, and audiometry. Avoid co-administration with other nephrotoxic/ototoxic drugs (loop diuretics, vancomycin, cisplatin, colistin).
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Amikacin Injection 100 mg per 2 ml
Amikacin is a semisynthetic aminoglycoside bactericidal antibiotic derived from kanamycin. It irreversibly binds to the bacterial 30S ribosomal subunit, inducing misreading of mRNA genetic code and interfering with protein translation. Particularly effective against multidrug-resistant Gram-negative bacillary infections (Pseudomonas aeruginosa, Klebsiella, Enterobacter, Proteus, Serratia, and E. coli) and Mycobacterium tuberculosis in specialized second-line regimens.
Amikacin Injection 500 mg per 2 ml
Amikacin is a semisynthetic aminoglycoside bactericidal antibiotic derived from kanamycin. It irreversibly binds to the bacterial 30S ribosomal subunit, inducing misreading of mRNA genetic code and interfering with protein translation. Particularly effective against multidrug-resistant Gram-negative bacillary infections (Pseudomonas aeruginosa, Klebsiella, Enterobacter, Proteus, Serratia, and E. coli) and Mycobacterium tuberculosis in specialized second-line regimens.